Edwards Lifesciences shows its product at the third CIIE. Photo: Courtesy of Edwards Lifesciences

 
Edwards Lifesciences participates in the fourth China International Import Expo (CIIE), and shows its innovative healthcare products.

Edwards aims to bring the world's leading treatment solutions and technologies to Chinese patients. To coincide with the 20th anniversary of its entry into China and to help develop China's healthcare industry, Edwards shows more innovative products and technologies at the CIIE in 2021. 

The company again shows the SAPIEN 3 transcatheter valve, which it showed at the CIIE in 2020. More than 500,000 patients around the world have benefited from treatment with the SAPIEN valves, and so can the Chinese patients. SAPIEN 3 is currently the only approved balloon-expandable aortic valve in China. It offers patients good clinical outcomes, shorter hospital stays, a shorter recovery time and quick relief of the symptoms of severe aortic stenosis. Thanks to the CIIE spillover effect, SAPIEN 3 has been used in nearly 50 hospitals in less than one year after its launch in China.

The next-generation HemoSphere monitoring platform with Hypotension Prediction Index (HPI) technology makes its debut at the Edwards' booth at CIIE. This first-of-its-kind technology detects the likelihood of a patient trending toward hypotension, or low blood pressure. It utilizes a data driven model developed from more than 200,000 patient events that indicates the likelihood of a hypotensive event before it occurs. This product is expected to be approved for launch in China in 2022.

Wang Huimin, corporate vice president for Edwards Lifesciences, responsible for business in the Asia-Pacific region. Photo: Courtesy of Edwards Lifesciences

 
Edwards' business in China covers more than 30 provinces, autonomous regions and municipalities, and its medical technologies have served more than 1.5 million Chinese patients. The company also believes that operating out of Shanghai provides access to key talent, said Wang Huimin, corporate vice president for Edwards Lifesciences, responsible for business in the Asia-Pacific region. 

Edwards has introduced more than 20 innovative and life-saving heart valve and critical care products over the last 20 years, Wang said, adding that through the Edwards Lifesciences Foundation, the company supports many philanthropic initiatives that increase access to healthcare.

During the fourth CIIE, Edwards and Mindray signs a memorandum of understanding, marking the first time Edwards has cooperated with a leading local medical company. This cooperation will leverage Edwards' expertise and clinical advantages in the field of advanced hemodynamics, as well as Mindray's extensive business network, to provide clinicians with accurate monitoring data and help them make tailored solutions to benefit a wider range of Chinese patients.

Wang told the Global Times that each region has different characteristics, and the company's business development and operations have been adjusted accordingly to adapt to the local market environment, while maintaining the rigorous standards used elsewhere around the world.

Edwards is the first multinational firm to offer transcatheter aortic valve replacement in China, Wang noted, adding that driven by their passion to help patients, the company will continue its investment in the domestic market while also bringing the latest technologies for Chinese patients in the fields of structural heart disease and critical care medicine. 

Edwards Lifesciences shows its product at the third CIIE. Photo: Courtesy of Edwards Lifesciences

 

Edwards Lifesciences participates in the fourth China International Import Expo (CIIE), and shows its innovative healthcare products.

Edwards aims to bring the world's leading treatment solutions and technologies to Chinese patients. To coincide with the 20th anniversary of its entry into China and to help develop China's healthcare industry, Edwards shows more innovative products and technologies at the CIIE in 2021. 

The company again shows the SAPIEN 3 transcatheter valve, which it showed at the CIIE in 2020. More than 500,000 patients around the world have benefited from treatment with the SAPIEN valves, and so can the Chinese patients. SAPIEN 3 is currently the only approved balloon-expandable aortic valve in China. It offers patients good clinical outcomes, shorter hospital stays, a shorter recovery time and quick relief of the symptoms of severe aortic stenosis. Thanks to the CIIE spillover effect, SAPIEN 3 has been used in nearly 50 hospitals in less than one year after its launch in China.

The next-generation HemoSphere monitoring platform with Hypotension Prediction Index (HPI) technology makes its debut at the Edwards' booth at CIIE. This first-of-its-kind technology detects the likelihood of a patient trending toward hypotension, or low blood pressure. It utilizes a data driven model developed from more than 200,000 patient events that indicates the likelihood of a hypotensive event before it occurs. This product is expected to be approved for launch in China in 2022.

Wang Huimin, corporate vice president for Edwards Lifesciences, responsible for business in the Asia-Pacific region. Photo: Courtesy of Edwards Lifesciences

 Edwards' business in China covers more than 30 provinces, autonomous regions and municipalities, and its medical technologies have served more than 1.5 million Chinese patients. The company also believes that operating out of Shanghai provides access to key talent, said Wang Huimin, corporate vice president for Edwards Lifesciences, responsible for business in the Asia-Pacific region. 

Edwards has introduced more than 20 innovative and life-saving heart valve and critical care products over the last 20 years, Wang said, adding that through the Edwards Lifesciences Foundation, the company supports many philanthropic initiatives that increase access to healthcare.

During the fourth CIIE, Edwards and Mindray signs a memorandum of understanding, marking the first time Edwards has cooperated with a leading local medical company. This cooperation will leverage Edwards' expertise and clinical advantages in the field of advanced hemodynamics, as well as Mindray's extensive business network, to provide clinicians with accurate monitoring data and help them make tailored solutions to benefit a wider range of Chinese patients.

Wang told the Global Times that each region has different characteristics, and the company's business development and operations have been adjusted accordingly to adapt to the local market environment, while maintaining the rigorous standards used elsewhere around the world.

Edwards is the first multinational firm to offer transcatheter aortic valve replacement in China, Wang noted, adding that driven by their passion to help patients, the company will continue its investment in the domestic market while also bringing the latest technologies for Chinese patients in the fields of structural heart disease and critical care medicine.